Ken Kang-Hsin Wang, PhD

FLASH radiotherapy delivers curative dose to tumor at ultra-high dose rates (UHDR,>40Gy/s) while mitigating normal tissue toxicity. However, data on late-responding tissues are limited, halting its safe clinical translation. Owing to its steep dose–response a...

Ultra-high-dose-rate (≥40 Gy/s, UHDR) FLASH radiotherapy (RT) has shown encouraging preclinical normal tissue sparing, with equal tumor control as conventional RT. A kV dual-tube system in parallel-opposed geometry has been proposed as a small-animal FLASH re...